| Market Cap | 17.76M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.1M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
| Sales | 125.2k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 24.00% |
| Dividend | N/A | Price/Book | 4.60 | EPS next 5Y | - | 52W High Chg | -38.00% |
| Recommedations | - | Quick Ratio | 17.66 | Shares Outstanding | 1.69B | 52W Low Chg | 130.00% |
| Insider Own | 40.58% | ROA | -26.67% | Shares Float | 1.05B | Beta | 0.73 |
| Inst Own | - | ROE | -61.85% | Shares Shorted/Prior | -/- | Price | 0.01 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 2,038 | Target Price | - |
| Oper. Margin | -343.96% | Earnings Date | Aug 30 | Volume | 20,000 | Change | 0.00% |
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
